ATS 2024 Final Program

Click on the session title to view the speakers

312

WEDNESDAY • MAY 22

that may be leveraged for prognostic enrichment and outcome/therapeutic response prediction. 8:15 Therapeutic Clinical Trials in ILA: What Do We Need and How Do We Get There? 8:30 The Pros and Cons of ILA Screening 8:45 High Resolution EB-OCT Imaging as a Novel Method for Prognostic Enrichment in ILA 9:00 Proteomics for Prognostic and Predictive Biomarkers in ILA 9:15 Using Spatial Transcriptomics in ILA to Identify New Biomarkers and Therapeutic Targets 9:30 Panel Discussion and Questions This session and the International Conference are supported BASIC • CLINICAL • TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE D4 LYMPHANGIOLEIOMYOMATOSIS: AT THE FOREFRONT OF SCIENTIFIC AND CLINICAL PROGRESS Assemblies on Clinical Problems; Respiratory Cell and Molecular Biology; Respiratory Structure and Function 8:15 a.m. - 9:45 a.m. Marriott Marquis San Diego Marina Grand Ballroom 2-4 (Lobby Level, North Tower) Target Audience All pulmonary providers, fellows in training, lab-based researchers Objectives At the conclusion of this session, the participant will be able to: • manage patients with LAM while integrating the latest evidence into their practice • describe new findings about our current understanding of LAM • apply cutting edge technologies to elucidate disease pathobiology Lymphangioleiomyomatosis (LAM) is a female-predominant, progressive, cystic lung neoplasm caused by mutations in the Tuberous Sclerosis Complex genes. Recent years have seen a tremendous progress in elucidating the genetic and molecular by an independent medical educational grant from Boehringer IngelheimPharmaceuticals, Inc. All CMEsessions have been planned and implemented in accordancewith the AccreditationCriteria of theAccreditationCouncil for ContinuingMedical Education (ACCME ® ) and are free of the control of ineligible companies (formerly commercial interests).

alterations that drive the pathobiology of LAM. The recent application of cutting-edge technologies such as single cell RNA sequencing and spatial transcriptomics has transformed our understanding of LAM, and offered new avenues for translation. Close partnership and integration of scientists, clinicians and patients has ensured seamless bedside translation of the scientific progress. This session will highlight the most recent advances in basic, translational and clinical progress in LAM. 8:15 A Patient's Perspective 8:19 Molecular Pathogenesis of LAM 8:38 Mechanisms of Matrix Degradation in LAM 8:57 New Insights into LAM Pathobiology 9:16 Clinical Advances in LAM 9:35 Panel Discussion D5 TIME-LIMITED TRIALS IN CRITICAL CARE Assemblies on Behavioral and Health Services Research; Critical Care 8:15 a.m. - 9:45 a.m. Marriott Marquis San Diego Marina Grand Ballroom 11-13 (Lobby Level, North Tower) Target Audience (1) Interprofessional and interdisciplinary professionals who care for patients with critical illness (2) Health services and clinical researchers (3) ICU medical directors, managers, and leaders within health systems Objectives At the conclusion of this session, the participant will be able to: • identify the essential elements of a time-limited trial in critical care and employ these elements when using time-limited trials in clinical practice • define a time-limited trial for patients with critical illness • describe how, if used inappropriately, time-limited trials could perpetuate unintended harm and inequities in critical care For more than two decades, the approach to patient care known as a “time-limited trial” has been discussed and endorsed by experts in palliative and critical care. Yet, there is a lack of consensus about what constitutes a time-limited trial, including its definition and essential elements. In 2022, ATS sponsored a BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM

ATS 2024 • San Diego, CA